TransCode Therapeutics (Rnaz)宣布收购Polynoma并获得CK Life Sciences子公司2500万美元战略融资,旨在组建一家首创的独特免疫肿瘤学和转移预防肿瘤学公司。
TransCode Therapeutics (Rnaz)宣布收购Polynoma并获得CK Life Sciences子公司2500万美元战略融资,旨在组建一家首创的独特免疫肿瘤学和转移预防肿瘤学公司。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.